Drug intelligence / Profile preview

goserelin + letrozole + ribociclib

Development stage: Unknown
Lead developer: Novartis
Modality: Peptides, Small Molecules
Administration: Oral, Subcutaneous

Overview

A combination therapy consisting of goserelin (an LHRH agonist), letrozole (an aromatase inhibitor), and ribociclib (a CDK4/6 inhibitor). This regimen is used for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer, particularly in pre/perimenopausal women and male patients. The combination works by suppressing hormone production (goserelin), blocking estrogen synthesis (letrozole), and inhibiting cell cycle progression (ribociclib) to prevent cancer cell growth and proliferation.

Targets

GnRHR (Gonadotropin-releasing hormone receptor)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on goserelin + letrozole + ribociclib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on goserelin + letrozole + ribociclib.

Explore the full profile